Clinical Trials Logo

Hereditary Angioedema clinical trials

View clinical trials related to Hereditary Angioedema.

Filter by:

NCT ID: NCT06467084 Not yet recruiting - Clinical trials for Hereditary Angioedema

Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

KONFIDENT-KID
Start date: June 24, 2024
Phase: Phase 3
Study type: Interventional

KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.

NCT ID: NCT06415448 Available - Clinical trials for Hereditary Angioedema

Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of the Expanded Access Program is to provide pre-approval access of donidalorsen to eligible patients with Hereditary Angioedema (HAE) who complete the ISIS 721744-CS3 clinical trial.

NCT ID: NCT06414252 Completed - Clinical trials for Hereditary Angioedema

Social Evaluated Cold Pressor Test in Hereditary Angioedema Patients

FROSEN
Start date: May 15, 2023
Phase:
Study type: Observational

This study aims to evaluate the differences in objective and subjective stress responses between patients with hereditary angioedema and healthy individuals to a stress-induced challenge like socially-evaluated cold pressure test. The study also investigates the role of psychological variables in influencing the stress response.

NCT ID: NCT06408805 Completed - Clinical trials for Hereditary Angioedema

Autonomic Nervous System Profile in Hereditary Angioedema

ANS-HAE
Start date: July 12, 2023
Phase:
Study type: Observational

The goal of this study is to compare the autonomic nervous system control of patients with hereditary angioedema to healthy individuals. The main questions it aims to answer are: Are there differences in the autonomic nervous system control between patients with hereditary angioedema and healthy individuals during short-term resting period and during orthostatic challenges? Are there differences in the autonomic nervous system control recorded over long-term periods (i.e. 24 hours)?

NCT ID: NCT06343779 Recruiting - Clinical trials for Hereditary Angioedema

Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

RAPIDe-3
Start date: February 26, 2024
Phase: Phase 3
Study type: Interventional

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryngeal attacks, in participants ≥12 to ≤75 years of age with HAE type 1 or type 2 (HAE-1/2), a proportion of whom are using long-term prophylactic medication for HAE.

NCT ID: NCT06262399 Enrolling by invitation - Clinical trials for Hereditary Angioedema

Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002

Start date: April 12, 2024
Phase:
Study type: Observational

This is a follow-up study of subjects who received NTLA-2002 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.

NCT ID: NCT06007677 Enrolling by invitation - Clinical trials for Hereditary Angioedema

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

Start date: September 26, 2023
Phase: Phase 2
Study type: Interventional

The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.

NCT ID: NCT05695248 Recruiting - Clinical trials for Hereditary Angioedema

A Study of STAR-0215 in Participants With Hereditary Angioedema

Start date: February 21, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1 dose of STAR-0215, and two other groups will get 2 doses of STAR-0215. Researchers will study the effects of STAR-0215 in participants with HAE as this is the first time that the drug has been given to participants with HAE.

NCT ID: NCT05691361 Recruiting - Clinical trials for Hereditary Angioedema

Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

Start date: December 14, 2022
Phase: Phase 1
Study type: Interventional

The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-324 in healthy volunteers (HV) and in patients with Hereditary Angioedema (HAE).

NCT ID: NCT05511922 Recruiting - Clinical trials for Hereditary Angioedema

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Start date: October 24, 2022
Phase: Phase 3
Study type: Interventional

This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.